CClinicalTrials.gg
RecruitingNCT06036381GLIO-RADUpdated Apr 9, 2025

Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis

An observational study in Glioma, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Tata Memorial Centre · Observational

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 7 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
1,000
Ages
1 Year and older
Sex
All
01

Study summary

Glioma are type of primary brain tumors arising within the substance of brain. Different type of gliomas are seen which are classified depending upon pathological examination and advanced molecular techniques, which help to determine the aggressiveness of the tumor and outcomes. Artificial intelligence uses advanced analytical process aided by computer which can be undertaken on the medical images. We plan to use artificial intelligence techniques to identify the abnormal areas within the brain representing tumor from the radiological images. Also, similar approach will be undertaken to classify gliomas with good or bad prognosis, to differentiate glioma from other type of brain tumors, and to detect response after treatment.

Read the detailed description

In the proposed retrospective study, images (MRI, CT, or PET) undertaken as part of standard of care (pre-treatment, post-operative, response assessment, and surveillance) will be analyzed. The DMG database maintaining records of patients registered in TMC neuro-oncology DMG will be screened to identify the patients eligible for the study. With approximately 500-600 gliomas seen annually and approximately 80-100 patients/year having pre-treatment imaging, we expect a ceiling of 1000 patients during 2010-2022, which will be the maximum number of patients used for the analysis. All the images will be downloaded from the PACS applying anonymization filters, with clinical records extracted by review of electronic medical records and radiation plans. Imaging pre-processing will be done, which will include skull stripping and registration across different modalities (e.g., MRI and CT) or different sequences (e.g., T1C, T2W, ADC) will be done using rigid or deformable algorithms as suited best for the modality. Image segmentation to classify the region of interest will be done and verified individually by a neuro-radiologist or nuclear medicine physician as appropriate. The segmentations will be done to identify T1-contrast enhancing region (CE), non-enhancing regions (NE), and necrosis (NEC) guided by T1-C, T2W, and T2-FLAIR areas. The contours and the images will be resampled to a uniform resolution for different sequences or modalities (e.g., T2W/ ADC/ PET) to match either with the 3D sequence (e.g., FSPGR sequence) or available images with the least slice thickness. Subsequently, normalization techniques (e.g., histogram normalization/ Z-score normalization) will be undertaken within the individual images and across the entire dataset to account or image heterogeneity, including field strength for MRI and different image acquisition parameters. For auto segmentation, both supervised and unsupervised machine learning algorithms will be applied. For the supervised model, the entire database will be split into training and test cohorts for the model and application development, respectively. The effectiveness of the automated model will be tested using the dice similarity coefficient between manually segmentation regions and AI-based segments. For prognostication of gliomas, the next step will include feature extraction, which will consist of first-order (including shape, histogram), second-order or higher-order (e.g., different texture features like GLCM, GLDM, GLSZM, etc.), or deep learning techniques will be employed. Delta-radiomics will include temporal changes in the radiomic features from different time points for the same patient within the entire volume and individual regions. Subsequently, feature reduction and selection techniques like LASSO, recursive feature elimination will be used to shortlist the number of features depending on the sample size. The outputs will be decided based on the modeling defined for specific class problems (e.g., tumor vs. edema, recurrence vs. pseudo progression, outcomes, tumor region of interest vs. non-tumoral area) as obtained from the clinical information. Any class imbalance will be addressed using methods like random subset sampling or SMOTE analysis for data augmentation of the minority class. Machine learning algorithms like LDA, k-NN, SVM, random forest, AdaBoost, etc., will be applied singularly or in combination as an ensembled classifier to find the model with best performance. Deep learning classifiers will be used along with feature-based modeling and compared to test the classifier's applicability. Validation techniques like leave-one-out validation, k-fold validation, and split (into training and test cohort) will be used to assess the stability of the machine learning model. Radiomic analysis will be done by data scientist/ study investigators with expertise in data analytics. All segmentations will be done on open-source software like ITK snap (itksnap.org) or 3D Slicer (slicer.org). Feature extraction and modeling will be done using open-source software like Python (python.org). With continuous advancements in computational science, available newer analytical techniques and platforms will be applied as appropriate by collaborators from Indian Statistical Institute, Kolkata, Machine Intelligence Unit by sharing of the anonymized data.

02

Conditions studied

  • Glioma

Browse trials for

Keywords

  • Glioma
  • Radiomics
  • Artificial Intelligence
  • Machine learning
03

In context

Glioma

1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 88 across 238 observational studies indexed under Glioma.

Browse Glioma studies →

Lead sponsor

Tata Memorial Centre is the lead sponsor of 63 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population will be according to the Inclusion and Exclusion Criteria . Study Includes vulnerable participants also. Minors (up to 18 years),Elderly

Inclusion criteria

  • Patients with glioma or glioma-mimicking pathology with imaging available in TMC between January 2010 and December 2022.

Exclusion criteria

Exclusion Criteria:

  • Imaging done outside TMC.
  • Motion artifacts or other artifacts causing image degradation.
  • Size of tumor or region of interest \< 1 cm in the largest dimension
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testRadiomic analysis of imaging - MRI, PET, CT

    Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.

06

What researchers measure

Primary outcomes

  1. Autosegmentation of tumor

    The correlation of tumor region between manual segmentation and artificial intelligence-based autosegmentation model will be assessed using the Dice coefficient of similarity.

    Time frame: 3 years

  2. Prognostication of gliomas

    Radiomic signature in prognostication of gliomas with estimation of progression-free survival and overall survival using Kaplan Meier plots and radiomics score-based nomograms.

    Time frame: 3 years

Secondary outcomes

  1. Response assessment in gliomas

    Response assessment of gliomas using artificial intelligence model-based prediction and comparison with actual response (like radionecrosis, progression) using confusion matrices and estimation of parameters like sensitivity, specificity, accuracy, area under curve.

    Time frame: 3 years

  2. Differentiation of glioma from non-glioma histology

    Use of radiomics model to differentiate gliomas from other brain tumors, with performance indices calculated using sensitivity, specificity, accuracy, area under curve.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • Tata Memorial Hospital
    Mumbai, Maharashtra 400012, India
    • Dr Archya Dasgupta, MD · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06036381
Lead sponsor
Tata Memorial Centre
Collaborators
Indian Statistical Institute, Kolkata
Responsible party
Dr Archya Dasgupta (Assistant Professor, Radiation Oncology, Tata Memorial Centre) — Principal investigator
First posted
Sep 13, 2023
Start date
Feb 15, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 9, 2025

Study contacts

Dr. ARCHYA DASGUPTA, MD
Contact
archya1010@gmail.com
022-24177000 ext. 6861
Dr. ARCHYA DASGUPTA, MD
principal investigator · Tata Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion